Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 341,300 | 238,200 | 108,400 | 43,400 | 249,700 |
| Depreciation Amortization | 900 | 20,000 | 13,500 | 6,200 | 3,000 |
| Income taxes - deferred | -123,100 | -91,800 | -56,900 | -15,600 | -56,700 |
| Accounts receivable | -39,800 | -41,800 | -28,900 | -11,300 | -89,300 |
| Other Working Capital | -19,200 | -113,500 | -117,900 | -31,600 | 28,200 |
| Other Operating Activity | 435,300 | 341,800 | 276,700 | 139,200 | 255,000 |
| Operating Cash Flow | $595,400 | $352,900 | $194,900 | $130,300 | $389,900 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,056,100 | -744,300 | -511,800 | -320,100 | -1,379,900 |
| PPE Investments | -38,200 | -30,900 | -22,800 | -11,200 | -28,300 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -31,300 |
| Sale Of Investment | 967,500 | 716,700 | 451,400 | 276,300 | 972,400 |
| Investing Cash Flow | $-126,800 | $-58,500 | $-83,200 | $-55,000 | $-467,100 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -308,800 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 122,100 | 112,100 | 85,700 | 69,900 | 65,300 |
| Common Stock Repurchased | -300,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 0 | -308,800 | -308,800 | 0 | 0 |
| Financing Cash Flow | $-486,700 | $-196,700 | $-223,100 | $69,900 | $65,300 |
| Exchange Rate Effect | N/A | 300 | 0 | N/A | 300 |
| Beginning Cash Position | 259,100 | 259,100 | 259,100 | 259,100 | 270,700 |
| End Cash Position | 241,000 | 357,100 | 147,700 | 404,300 | 259,100 |
| Net Cash Flow | $-18,100 | $98,000 | $-111,400 | $145,200 | $-11,600 |
| Free Cash Flow | |||||
| Operating Cash Flow | 595,400 | 352,900 | 194,900 | 130,300 | 389,900 |
| Capital Expenditure | -38,200 | -30,900 | -22,800 | -11,200 | -28,300 |
| Free Cash Flow | 557,200 | 322,000 | 172,100 | 119,100 | 361,600 |